Search

Your search keyword '"Barranger A"' showing total 2,608 results
Start Over Author "Barranger A"
2,608 results on '"Barranger A"'

2. Non-genetic indications for risk reducing mastectomies: Guidelines of the national college of French gynecologists and obstetricians (CNGOF)

Author

Mathelin, Carole, Barranger, Emmanuel, Boisserie-Lacroix, Martine, Boutet, Gérard, Brousse, Susie, Chabbert-Buffet, Nathalie, Coutant, Charles, Daraï, Emile, Delpech, Yann, Duraes, Martha, Espié, Marc, Fornecker, Luc, Golfier, François, Grosclaude, Pascale, Hamy, Anne Sophie, Kermarrec, Edith, Lavoué, Vincent, Lodi, Massimo, Luporsi, Élisabeth, Maugard, Christine M, Molière, Sébastien, Seror, Jean-Yves, Taris, Nicolas, Uzan, Catherine, Vaysse, Charlotte, and Fritel, Xavier

Published
2024
Full Text
View/download PDF

3. Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)

Author

Mathelin, C, Barranger, E, Boisserie-Lacroix, M, Boutet, G, Brousse, S, Chabbert-Buffet, N, Coutant, C, Daraï, E, Delpech, Y, Duraes, M, Espié, M, Golfier, F, Hamy, AS, Kermarrec, E, Lavoué, V, Lodi, M, Luporsi, É, Maugard, C, Molière, S, Seror, JY, Taris, N, Uzan, C, Vaysse, C, and Fritel, X

Published
2024
Full Text
View/download PDF

7. Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results

Author

Marie-Eve Chand-Fouché, Claudine Colnard, Jocelyn Gal, Daniel Lam Cham Kee, Catherine Dejean, Matthieu Gautier, Julien Feuillade, Aurélia Mana, Yves Fouché, Yann Delpech, Magali Dejode, Jean-Pierre Gérard, and Emmanuel Barranger

Subjects
Papillon+ system, Breast IORT, Brachytherapy, High dose rate, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background and Purpose: Breast intra operative radiation therapy has been evaluated with different systems delivering 20–21 Gy with treatment times around 30 min. Papillon + TM Contact X-ray machine was designed to produce a 50 kVp beam with a high dose rate ≥ 15 Gy/minute. A pilot study with the first prototype was conducted in Nice. Materials and methods: The inclusion criteria were age ≥ 60 years, unifocal ductal breast adenocarcinoma ≤ 2.5 cm, grade 1–2. Surgical local excision with sentinel node dissection was performed and the applicator was placed in the tumor bed after excision with a prescribed dose of 20 Gy. The main end point of the study was the doses measured with the Gafchromic films; two were located at the skin surface and two in the excision cavity. Secondary endpoints were early toxicity and relapse free survival. Results: Between 10/2018 and 09/2019, 26 patients were included. Mean Gafchromic doses were 18.8 Gy ± 2 Gy at the south pole, 15.6 Gy ± 2.81 Gy at the equator and 2.5 Gy ± 1.67 Gy at the skin. With a median follow-up time of 12 months, no skin or subcutaneous toxicity > grade 2, no local relapse and no metastasis were observed. Conclusion: This is the first phase II study testing the Papillon + tm system for breast IORT with in vivo dosimetry measurements and reassuring clinical data.

Published
2023
Full Text
View/download PDF

9. Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials

Author

Uzan, C., Morice, P., Stoeckle, E., Fourchotte, V., Querleu, D., Baron, M., Ott, B., Darai, E., Leveque, J., Lanvin, D., Pomel, C., Marret, H., Leblanc, E., Houvenaeghel, G., Rouanet, P., Descamps, P., Mage, G., Graesslin, O., Baldauf, J.J., Classe, J.M., Raudrant, D., Conri, V., Douvier, S., Barranger, E., Leguevaque, P., Fouché, Y., Boulanger, L., Magaud, L., Schott, A.M., Bouttitie, F., Kissel, M., Balaya, V., Guani, B., Mathevet, P., and Lécuru, F.

Published
2023
Full Text
View/download PDF

13. Eliciting the Endowment Effect under Assigned Ownership

Author

Barranger, Patrick, Nair, Rohit, Mulla, Rob, and Conner, Shane

Subjects
Economics - General Economics
Abstract

In this study we present evidence that endowment effect can be elicited merely by assigned ownership. Using Google Customer Survey, we administered a survey were participants (n=495) were randomly split into 4 groups. Each group was assigned ownership of either legroom or their ability to recline on an airline. Using this experiment setup we were able to generate endowment effect, a 15-20x (at p<0.05) increase between participant's willingness to pay (WTP) and their willingness to accept (WTA)., Comment: 14 pages, 12 figures

Published
2018

14. Monitoring Breast Cancer Care Quality at National and Local Level Using the French National Cancer Cohort

Author

Houzard, Sophie, Courtois, Emilie, Le Bihan Benjamin, Christine, Erbault, Marie, Arnould, Laurent, Barranger, Emmanuel, Coussy, Florence, Couturaud, Benoît, Cutuli, Bruno, de Cremoux, Patricia, de Reilhac, Pia, de Seze, Chantal, Foucaut, Aude-Marie, Gompel, Anne, Honoré, Stéphane, Lesur, Anne, Mathelin, Carole, Verzaux, Laurent, and Bousquet, Philippe-Jean

Published
2022
Full Text
View/download PDF

15. Indications des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF)

Author

Mathelin, Carole, Barranger, Emmanuel, Boisserie-Lacroix, Martine, Boutet, Gérard, Brousse, Susie, Chabbert-Buffet, Nathalie, Coutant, Charles, Daraï, Emile, Delpech, Yann, Duraes, Martha, Espié, Marc, Fornecker, Luc, Golfier, François, Grosclaude, Pascale, Hamy, Anne Sophie, Kermarrec, Edith, Lavoué, Vincent, Lodi, Massimo, Luporsi, Élisabeth, Maugard, Christine M., Molière, Sébastien, Seror, Jean-Yves, Taris, Nicolas, Uzan, Catherine, Vaysse, Charlotte, and Fritel, Xavier

Published
2022
Full Text
View/download PDF

16. Modalités et morbidité des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF)

Author

Mathelin, C., Barranger, E., Boisserie-Lacroix, M., Boutet, G., Brousse, S., Chabbert-Buffet, N., Coutant, C., Daraï, E., Delpech, Y., Duraes, M., Espié, M., Golfier, F., Hamy, A.S., Kermarrec, E., Lavoué, V., Lodi, M., Luporsi, É., Maugard, C., Molière, S., Seror, J.-Y., Taris, N., Uzan, C., Vaysse, C., and Fritel, X.

Published
2022
Full Text
View/download PDF

18. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

Author

Blay, J.Y., Boucher, S., Le Vu, B., Cropet, C., Chabaud, S., Perol, D., Barranger, E., Campone, M., Conroy, T., Coutant, C., De Crevoisier, R., Debreuve-Theresette, A., Delord, J.P., Fumoleau, P., Gentil, J., Gomez, F., Guerin, O., Jaffré, A., Lartigau, E., Lemoine, C., Mahe, M.A., Mahon, F.X., Mathieu-Daude, H., Merrouche, Y., Penault-Llorca, F., Pivot, X., Soria, J.C., Thomas, G., Vera, P., Vermeulin, T., Viens, P., Ychou, M., and Beaupere, S.

Published
2021
Full Text
View/download PDF

20. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database

Author

De Nonneville, Alexandre, Zemmour, Christophe, Frank, Sophie, Joly, Florence, Ray-Coquard, Isabelle, Costaz, Hèlène, Classe, Jean-Marc, Floquet, Anne, De la Motte Rouge, Thibault, Colombo, Pierre-Emmanuel, Sauterey, Baptiste, Leblanc, Eric, Pomel, Christophe, Marchal, Frédéric, Barranger, Emmanuel, Savoye, Aude-Marie, Guillemet, Cécile, Petit, Thierry, Pautier, Patricia, Rouzier, Roman, Gladieff, Laurence, Simon, Gaëtane, Courtinard, Coralie, and Sabatier, Renaud

Published
2021
Full Text
View/download PDF

22. Concepts in Gene Therapy

Author

Michael Strauss, John A. Barranger, Michael Strauss, John A. Barranger

Published
2020

23. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

Author

Aapro, Matti, Al-Ghazali, Hesham, Bachelot, Thomas, Barranger, Emmanuel, Berrada, Narjiss, Bidard, François-Clément, Bounedjar, Adda, Boussen, Hamouda, Campone, Mario, Cardoso, Fatima, Ceugnart, Luc, Classe, Jean-Marc, Cohen, Monique, Coutant, Charles, Cutuli, Bruno, Dalenc, Florence, Dieras, Véronique, Dohollou, Nadine, Giacchetti, Sylvie, Goncalves, Anthony, Freyer, Gilles, Hannoun-Levi, Jean-Michel, Hardy-Bessard, Anne-Claire, Jacquin, Jean-Philippe, Jacot, William, Kerrou, Khaldoun, Ladoire, Sylvain, Lerebours, Florence, Levy, Christelle, Llombart-Cussac, Antonio, Loirat, Delphine, Thomassin, Isabelle, Piccart, Martine, Petit, Thierry, Radosevic-Robin, Nina, Rotenberg, Luc, Rouzier, Roman, Salmon, Rémy, Vincent-Salomon, Anne, Spano, Jean-Philippe, Tallet, Agnès, Teixera, Luis, Tredan, Olivier, Verret, Benjamin, Zarca, Daniel, Zelek, Laurent, Zerbib, Eric, Gligorov, Joseph, Benderra, Marc-Antoine, Barthere, Xavier, de Forceville, Louise, Antoine, Eric Charles, Cottu, Paul Henri, Delaloge, Suzette, Pierga, Jean-Yves, Belkacemi, Yazid, Houvenaegel, Gilles, Pujol, Pascal, Rivera, Sofia, Spielmann, Marc, Penault-Llorca, Frédérique, and Namer, Moise

Published
2023
Full Text
View/download PDF

24. COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)

Author

Gligorov, Joseph, Bachelot, Thomas, Pierga, Jean-Yves, Antoine, Eric-Charles, Balleyguier, Corinne, Barranger, Emmanuel, Belkacemi, Yazid, Bonnefoi, Hervé, Bidard, François-Clément, Ceugnart, Luc, Classe, Jean-Marc, Cottu, Paul, Coutant, Charles, Cutuli, Bruno, Dalenc, Florence, Darai, Emile, Dieras, Veronique, Dohollou, Nadine, Giacchetti, Sylvie, Goncalves, Anthony, Hardy-Bessard, Anne-Claire, Houvenaeghel, Gilles, Jacquin, Jean-Philippe, Jacot, William, Levy, Christelle, Mathelin, Carole, Nisand, Israel, Petit, Thierry, Poncelet, Edouard, Rivera, Sofia, Rouzier, Roman, Salmon, Rémy, Scotté, Florian, Spano, Jean-Philippe, Uzan, Catherine, Zelek, Laurent, Spielmann, Marc, Penault-Llorca, Frédérique, Namer, Moise, and Delaloge, Suzette

Published
2020
Full Text
View/download PDF

29. Comparison of 3 γ-probes for simultaneous iodine-125-seed and technetium-99m breast cancer surgery: NEMA standard characterisation with extended processing

Author

Christopher Hoog, Pierre-Malick Koulibaly, Catherine Dejean, Tom Desdoits, Olivier Humbert, Emmanuel Barranger, and Jacques Darcourt

Subjects
Breast surgery, γ-Probes, Radioactive seed localisation, NEMA testing, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

Abstract Purpose Iodine-125 (125I) seeds can be used as landmarks to locate non-palpable breast lesions instead of implanting metal wires. This relatively new technique requires a nuclear probe usually used for technetium-99m (99mTc) sentinel node detection. This study aimed to compare the performances of different probes and valid the feasibility of this technique, especially in the case of simultaneous 125I-seed and 99mTc breast cancer surgery. Methods Three probes with different features (SOE-3211, SOE-3214 and GammaSUP-II) were characterised according to the NEMA NU3-2004 standards for a 99mTc source and a 125I-seed. Several tests such as sensitivity, linearity or spatial resolution allowed an objective comparison of their performances. NEMA testing was extended to work on signals discrimination in case of simultaneous detection of two different sources (innovative figure of merit “Shift Index”) and to assess the 99mTc scatter fraction, a useful parameter for the improvement of the probes in terms of detector materials and electronic system. Results Although the GammaSUP-II probe saturated at a lower activity (1.6 MBq at 10 mm depth), it allowed better sensitivity and spatial resolution at the different NEMA tests performed with the 99mTc source (7865 cps/MBq and 15 mm FWHM at 10 mm depth). With the 125I-seed, the GammaSUP-II was the most sensitive probe (3106 cps/MBq at 10 mm depth) and the SOE-3211 probe had the best spatial resolution (FWHM 20 mm at 10 mm depth). The SOE-3214 probe was more efficient on discriminating 125I from 99mTc in case of simultaneous detection. The SOE probes were more efficient concerning 99mTc scatter fraction assessments. The SOE-3211 probe, with overall polyvalent performances, seemed to be an interesting trade-off for detection of both 125I and 99mTc. Conclusion The three probes showed heterogeneous performances but were all suitable for simultaneous 99mTc sentinel node and 125I-seed detection. This study provides an objective and innovative methodology to compare probes performances and then choose the best trade-off regarding their expected use.

Published
2020
Full Text
View/download PDF

30. DPD status and fluoropyrimidines-based treatment: high activity matters too

Author

Emmanuel Chamorey, Eric Francois, Marie-Christine Etienne, Jean-Marc Ferrero, Frederic Peyrade, Emmanuel Barranger, Alexandre Bozec, Rémy Largillier, Ophelie Cassuto, Julien Viotti, Renaud Schiappa, and Gérard Milano

Subjects
Dihydropyrimidine dehydrogenase, Capecitabine, 5-fluorouracil, Digestive neoplasms, Breast neoplasms, Head and neck neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Dihydropyrimidine dehydrogenase (DPD) status is an indicator of a marked risk for toxicity following fluoropyrimidine (FP)-based chemotherapy. This notion is well-established for low DPD status but little is known about the clinical impact of high DPD activity. This study examined the possible link between high intrinsic lymphocytic DPD activity and overall survival, progression free survival and response to FP-based treatment in patients treated in our institution. Methods Lymphocytic DPD activity was assessed in a group of 136 patients receiving FP-based chemotherapy from 2004 to 2016. There were 105 digestive (77.2%), 24 breast (17.6%) and 7 head and neck cancers (5.2%). Cox or logistic regression models were applied with adjustment on all confounding factors that could modify OS, PFS or response. All models were stratified on the three cancer locations. A cut-off for DPD activity was assessed graphically and analytically. Results An optimal cut-off for DPD activity at 0.30 nmol/min/mg protein was identified as the best value for discriminating survivals and response. In multivariate analysis, individual lymphocytic DPD activity was significantly related to overall survival (p = 0.013; HR: 3.35 CI95%[1.27–8.86]), progression-free survival (p

Published
2020
Full Text
View/download PDF

34. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023

Author

Gligorov, Joseph, primary, Benderra, Marc-Antoine, additional, Barthere, Xavier, additional, de Forceville, Louise, additional, Antoine, Eric Charles, additional, Cottu, Paul Henri, additional, Delaloge, Suzette, additional, Pierga, Jean-Yves, additional, Belkacemi, Yazid, additional, Houvenaegel, Gilles, additional, Pujol, Pascal, additional, Rivera, Sofia, additional, Spielmann, Marc, additional, Penault-Llorca, Frédérique, additional, Namer, Moise, additional, Aapro, Matti, additional, Al-Ghazali, Hesham, additional, Bachelot, Thomas, additional, Barranger, Emmanuel, additional, Berrada, Narjiss, additional, Bidard, François-Clément, additional, Bounedjar, Adda, additional, Boussen, Hamouda, additional, Campone, Mario, additional, Cardoso, Fatima, additional, Ceugnart, Luc, additional, Classe, Jean-Marc, additional, Cohen, Monique, additional, Coutant, Charles, additional, Cutuli, Bruno, additional, Dalenc, Florence, additional, Dieras, Véronique, additional, Dohollou, Nadine, additional, Giacchetti, Sylvie, additional, Goncalves, Anthony, additional, Freyer, Gilles, additional, Hannoun-Levi, Jean-Michel, additional, Hardy-Bessard, Anne-Claire, additional, Jacquin, Jean-Philippe, additional, Jacot, William, additional, Kerrou, Khaldoun, additional, Ladoire, Sylvain, additional, Lerebours, Florence, additional, Levy, Christelle, additional, Llombart-Cussac, Antonio, additional, Loirat, Delphine, additional, Thomassin, Isabelle, additional, Piccart, Martine, additional, Petit, Thierry, additional, Radosevic-Robin, Nina, additional, Rotenberg, Luc, additional, Rouzier, Roman, additional, Salmon, Rémy, additional, Vincent-Salomon, Anne, additional, Spano, Jean-Philippe, additional, Tallet, Agnès, additional, Teixera, Luis, additional, Tredan, Olivier, additional, Verret, Benjamin, additional, Zarca, Daniel, additional, Zelek, Laurent, additional, and Zerbib, Eric, additional

Published
2023
Full Text
View/download PDF

36. Liste des auteurs

Author

Philippe, Deruelle, primary, Gilles, Kayem, additional, Loïc, Sentilhes, additional, Catherine, Arvieux, additional, Emmanuel, Barranger, additional, Barry Delongchamps, N., additional, Alexandra, Benachi, additional, Amaury, Brot, additional, Dominique, Cabrol, additional, Frédéric, Coatleven, additional, Xavier, Deffieux, additional, Alix, Defline, additional, Pierre, Delorme, additional, Philippe, Deruelle, additional, Hervé, Fernandez, additional, Arthur, Foulon, additional, Alizée, Froeliger, additional, Florent, Fuchs, additional, François, Goffinet, additional, Amina, Hamidouche, additional, Melissa, Hourbracq, additional, Clémence, Houssin, additional, Olivier, Le Dref, additional, Audrey, Leroy, additional, Véronique, Leroy, additional, Christine, Louis-Sylvestre, additional, Hugo, Madar, additional, Louis, Marcellin, additional, Aurélien, Mattuizzi, additional, Alexandre, Mignon, additional, Cyril, Raiffort, additional, Fabian, Reche, additional, Benoît, Resch, additional, Marie, Sarrau, additional, Marie-Victoire, Senat, additional, Fabrice, Sergent, additional, Stéphane, Silvera, additional, Marie-Charlotte, Soudan, additional, Aude, Ricbourg, additional, Myriam, Toumi, additional, Olivier, Vignaux, additional, and Marie, Vincienne, additional

Published
2020
Full Text
View/download PDF

38. Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials

Author

M. Kissel, V. Balaya, B. Guani, L. Magaud, P. Mathevet, F. Lécuru, C. Uzan, P. Morice, E. Stoeckle, V. Fourchotte, D. Querleu, M. Baron, B. Ott, E. Darai, J. Leveque, D. Lanvin, C. Pomel, H. Marret, E. Leblanc, G. Houvenaeghel, P. Rouanet, P. Descamps, G. Mage, O. Graesslin, J.J. Baldauf, J.M. Classe, D. Raudrant, V. Conri, S. Douvier, E. Barranger, P. Leguevaque, Y. Fouché, L. Boulanger, A.M. Schott, and F. Bouttitie

Subjects
Oncology, Obstetrics and Gynecology
Published
2023

40. Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: Early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial

Author

Hannoun-Lévi, Jean-Michel, Cham Kee, Daniel Lam, Gal, Jocelyn, Schiappa, Renaud, Hannoun, Arthur, Gautier, Mathieu, Boulahssass, Rabia, Peyrottes, Isabelle, Barranger, Emmanuel, Ferrero, Jean-Marc, Chand, Marie-Eve, and Doyen, Jérôme

Published
2018
Full Text
View/download PDF

41. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study

Author

Classe, Jean-Marc, Loaec, Cecile, Gimbergues, P., Alran, S., de Lara, C. Tunon, Dupre, P. F., Rouzier, Roman, Faure, C., Paillocher, N., Chauvet, M. P., Houvenaeghel, G., Gutowski, M., De Blay, P., Verhaeghe, J. L., Barranger, E., Lefebvre, C., Ngo, C., Ferron, G., Palpacuer, C., and Campion, L.

Published
2019
Full Text
View/download PDF

42. Efficacy of chemotherapy according toBRCAstatus in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse

Author

Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, Laurence Gladieff, Christophe Pomel, Pierre-Emmanuel Colombo, Jean-Marc Classe, Marion Chevrier, Florence Joly, Thibault De la Motte Rouge, Anne Floquet, Renaud Sabatier, Emmanuel Barranger, Hélène Costaz, Eric Leblanc, Frédéric Marchal, Patricia Pautier, Lise Bosquet, and Manuel Rodrigues

Subjects
Oncology, Obstetrics and Gynecology
Abstract

ObjectiveChemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According toin vitrodata,BRCAmutated patients are sensitive to replicative stress agents butBRCAstatus is not yet used for the choice of chemotherapy at relapse. Our aim was to assess these doublets according toBRCAstatus in first platinum-sensitive relapse.MethodsThe ESME ovarian cancer database comprises a multicenter retrospective cohort of patients with ovarian cancer treated in French cancer centers between January 2011 and December 2017. Patients with high-grade serous ovarian cancers at first platinum-sensitive relapse who received one of these doublets were included. The objective was to compare progression-free survival of each chemotherapy doublet according toBRCAstatus.ResultsAmong the 10 263 patients in the database, 1539 patients had a first platinum-sensitive relapse: 825BRCAwild type patients (53.6%) and 304BRCAmutated patients (19.8%) (7 patients had a homologous recombination mutation andBRCAstatus was unkown for 403 patients). Median progression-free survival was longer inBRCAmutated patients than inBRCAwild type patients when receiving carboplatin/pegylated liposomal doxorubicin without maintenance treatment (15.8 vs 11.8 months; pBRCAwild type patients without maintenance, better progression-free survival occurred with carboplatin/paclitaxel (median progression-free survival 14.3 months) than with carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin (9.8 and 11.8 months, respectively; p=0.017). InBRCAmutated patients without maintenance, there was no difference between the three doublets (median progression-free survival of 14.6, 12.0, and 15.8 months with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin, respectively; p=0.40).ConclusionWhile treatment with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin shows comparable efficacy inBRCAmutated patients, treatment with carboplatin/paclitaxel appears to be more effective than carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin inBRCAwild type patients with high-grade serous ovarian cancers at first platinum-sensitive relapse.

Published
2023

45. Therapeutic escalation – De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB)

Author

Houvenaeghel, Gilles, Lambaudie, Eric, Cohen, Monique, Classe, Jean-Marc, Reyal, Fabien, Garbay, Jean-Rémy, Giard, Sylvia, Chopin, Nicolas, Martinez, Alejandra, Rouzier, Roman, Daraï, Emile, Colombo, Pierre Emmanuel, Coutant, Charles, Gimbergues, Pierre, Azuar, Pierre, Villet, Richard, Tunon de Lara, Christine, Barranger, Emmanuel, Sabiani, Laura, and Goncalves, Anthony

Published
2017
Full Text
View/download PDF

46. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study

Author

Sims, KB, Pastores, GM, Weinreb, NJ, Barranger, J, Rosenbloom, BE, Packman, S, Kaplan, P, Mankin, H, Xavier, R, Angell, J, Fitzpatrick, MA, and Rosenthal, D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Rare Diseases, Pain Research, Osteoporosis, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Musculoskeletal, Bone Density, Bone Diseases, Bone Diseases, Metabolic, Cohort Studies, Female, Gaucher Disease, Glucosylceramidase, Humans, Longitudinal Studies, Male, Prospective Studies, Spine, Genetics, Genetics & Heredity, Clinical sciences
Abstract

Progressive skeletal disease accounts for some of the most debilitating complications of type 1 Gaucher disease. In this 48-month, prospective, non-randomized, open-label study of the effect of enzyme replacement therapy on bone response, 33 imiglucerase-naïve patients (median age 43 years with one or more skeletal manifestations such as osteopenia, history of bone crisis, or other documented bone pathology) received imiglucerase 60 U/kg/2 weeks. Substantial improvements were observed in bone pain (BP), bone crises (BC), and bone mineral density (BMD). Improvements in BP were observed at 3 months (p < 0.001 vs baseline) and continued progressively throughout the study, with 39% of patients reporting pain at 48 months vs 73% at baseline. Eleven of the 13 patients with a pre-treatment history of BC had no recurrences. Biochemical markers for bone formation increased; markers for bone resorption decreased. Steady improvement of spine and femoral neck BMD, measured using dual-energy X-ray absorptiometry was noted. Mean Z score for spine increased from -0.72 +/- 1.302 at baseline to near-normal levels (-0.09 +/- 1.503) by month 48 (p = 0.042) and for femoral neck from -0.59 +/- 1.352 to -0.17 +/- 1.206 (p = 0.035) at month 36. This increase was sustained at 48 months. With imiglucerase treatment, patients should anticipate resolution of BC, rapid improvement in BP, increases in BMD, and decreased skeletal complications.

Published
2008

49. RUBY: Natural Language Processing of French Electronic Medical Records for Breast Cancer Research

Author

Renaud Schiappa, Sara Contu, Dorian Culie, Brice Thamphya, Yann Chateau, Jocelyn Gal, Caroline Bailleux, Juliette Haudebourg, Jean-Marc Ferrero, Emmanuel Barranger, and Emmanuel Chamorey

Subjects
Electronic Health Records, Humans, Breast Neoplasms, Female, General Medicine, France, Natural Language Processing, Semantics
Abstract

PURPOSE Electronic medical records are a valuable source of information about patients' clinical status but are often free-text documents that require laborious manual review to be exploited. Techniques from computer science have been investigated, but the literature has marginally focused on non-English language texts. We developed RUBY, a tool designed in collaboration with IBM—France to automatically structure clinical information from French medical records of patients with breast cancer. MATERIALS AND METHODS RUBY, which exploits state-of-the-art Named Entity Recognition models combined with keyword extraction and postprocessing rules, was applied on clinical texts. We investigated the precision of RUBY in extracting the target information. RESULTS RUBY has an average precision of 92.8% for the Surgery report, 92.7% for the Pathology report, 98.1% for the Biopsy report, and 81.8% for the Consultation report. CONCLUSION These results show that the automatic approach has the potential to effectively extract clinical knowledge from an extensive set of electronic medical records, reducing the manual effort required and saving a significant amount of time. A deeper semantic analysis and further understanding of the context in the text, as well as training on a larger and more recent set of reports, including those containing highly variable entities and the use of ontologies, could further improve the results.

Published
2023

50. Gelatin methacrylate hydrogel with drug-loaded polymer microspheres as a new bioink for 3D bioprinting

Author

Adam Mirek, Habib Belaid, Aleksandra Bartkowiak, Fanny Barranger, Fanny Salmeron, Marilyn Kajdan, Marcin Grzeczkowicz, Vincent Cavaillès, Dorota Lewińska, Mikhael Bechelany, Nalecz Institute of Biocybernetics and Biomedical Engineering (IBIB), Institut Européen des membranes (IEM), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Université de Montpellier (UM), Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, and Gulf University for Science and Technology (GUST)

Subjects
Biomaterials, 3D bioprinting, Bioink, Drug delivery, Biomedical Engineering, [CHIM]Chemical Sciences, Bioengineering, Gelatin methacrylate, Microspheres, Cross-linking
Abstract

International audience; 3D bioprinted hydrogel constructs are advanced systems of a great drug delivery application potential. One of the bioinks that has recently gained a lot of attention is gelatin methacrylate (GelMA) hydrogel exhibiting specific properties, including UV cross-linking possibility. The present study aimed to develop a new bioink composed of GelMA and gelatin modified by addition of polymer (polycaprolactone or polyethersulfone) microspheres serving as bioactive substance carriers. The prepared microspheres suspension in GelMA/gelatin bioink was successfully bioprinted and subjected to various tests, which showed that the addition of microspheres and their type affects the physicochemical properties of the printouts. The hydrogel stability and structure was examined using scanning electron and optical microscopy, its thermal properties with differential scanning calorimetry and thermogravimetric analysis and its biocompatibility on HaCaT cells using viability assay and electron microscopy. Analyses also included tests of hydrogel equilibrium swelling ratio and release of marker substance. Subsequently, the matrices were loaded with ampicillin and the antibiotic release was validated by monitoring the antibacterial activity on Staphylococcus aureus and Escherichia coli. It was concluded that GelMA/gelatin bioink is a good and satisfying material for potential medical use. Depending on the polymer used, the addition of microspheres improves its structure, thermal and drug delivery properties.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results